Medipharm Labs Corp Stock Performance
| LABS Stock | CAD 0.07 0.01 7.14% |
Medipharm Labs has a performance score of 2 on a scale of 0 to 100. The company secures a Beta (Market Risk) of -1.03, which conveys a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Medipharm Labs are expected to decrease slowly. On the other hand, during market turmoil, Medipharm Labs is expected to outperform it slightly. Medipharm Labs Corp right now secures a risk of 5.45%. Please verify Medipharm Labs Corp semi deviation, coefficient of variation, jensen alpha, as well as the relationship between the downside deviation and standard deviation , to decide if Medipharm Labs Corp will be following its current price movements.
Risk-Adjusted Performance
2 of 100
Weak | Strong |
Weak
Compared to the overall equity markets, risk-adjusted returns on investments in Medipharm Labs Corp are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. In spite of very unfluctuating basic indicators, Medipharm Labs may actually be approaching a critical reversion point that can send shares even higher in December 2024. ...more
Last Split Factor 1:2 | Last Split Date 2018-10-04 |
1 | MediPharm Labs Sets Q3 Earnings Release Date, Skips Investor Call MEDIF Stock News - StockTitan | 11/11/2024 |
2 | MEDIF Net Income -9.96 Mil - GuruFocus.com | 11/19/2024 |
| Begin Period Cash Flow | 24.1 M |
Medipharm |
Medipharm Labs Relative Risk vs. Return Landscape
If you would invest 6.50 in Medipharm Labs Corp on August 26, 2024 and sell it today you would earn a total of 0.00 from holding Medipharm Labs Corp or generate 0.0% return on investment over 90 days. Medipharm Labs Corp is generating 0.1457% of daily returns and assumes 5.4534% volatility on return distribution over the 90 days horizon. Simply put, 48% of stocks are less volatile than Medipharm, and 98% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Medipharm Labs Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Medipharm Labs' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Medipharm Labs Corp, and traders can use it to determine the average amount a Medipharm Labs' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0267
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | LABS | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.45 actual daily | 48 52% of assets are more volatile |
Expected Return
| 0.15 actual daily | 2 98% of assets have higher returns |
Risk-Adjusted Return
| 0.03 actual daily | 2 98% of assets perform better |
Based on monthly moving average Medipharm Labs is performing at about 2% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Medipharm Labs by adding it to a well-diversified portfolio.
Medipharm Labs Fundamentals Growth
Medipharm Stock prices reflect investors' perceptions of the future prospects and financial health of Medipharm Labs, and Medipharm Labs fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Medipharm Stock performance.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.0717 | ||||
| Profit Margin | (0.35) % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | 14.28 M | ||||
| Shares Outstanding | 411.07 M | ||||
| Price To Earning | 172.00 X | ||||
| Price To Book | 0.59 X | ||||
| Price To Sales | 0.71 X | ||||
| Revenue | 33.06 M | ||||
| Gross Profit | (13.42 M) | ||||
| EBITDA | (16.35 M) | ||||
| Net Income | (13.08 M) | ||||
| Cash And Equivalents | 24.14 M | ||||
| Cash Per Share | 0.20 X | ||||
| Total Debt | 2.29 M | ||||
| Debt To Equity | 0.14 % | ||||
| Current Ratio | 3.19 X | ||||
| Book Value Per Share | 0.13 X | ||||
| Cash Flow From Operations | (11.76 M) | ||||
| Earnings Per Share | (0.03) X | ||||
| Market Capitalization | 26.72 M | ||||
| Total Asset | 63.94 M | ||||
| Retained Earnings | (176.73 M) | ||||
| Working Capital | 25.77 M | ||||
About Medipharm Labs Performance
By examining Medipharm Labs' fundamental ratios, stakeholders can obtain critical insights into Medipharm Labs' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Medipharm Labs is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 132.80 | 225.29 | |
| Return On Tangible Assets | (0.21) | (0.22) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.20) | (0.21) | |
| Return On Equity | (0.25) | (0.26) |
Things to note about Medipharm Labs Corp performance evaluation
Checking the ongoing alerts about Medipharm Labs for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Medipharm Labs Corp help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Medipharm Labs Corp had very high historical volatility over the last 90 days | |
| Medipharm Labs Corp has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 33.06 M. Net Loss for the year was (13.08 M) with loss before overhead, payroll, taxes, and interest of (13.42 M). | |
| Medipharm Labs Corp has accumulated about 24.14 M in cash with (11.76 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.2, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: MEDIF Net Income -9.96 Mil - GuruFocus.com |
- Analyzing Medipharm Labs' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Medipharm Labs' stock is overvalued or undervalued compared to its peers.
- Examining Medipharm Labs' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Medipharm Labs' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Medipharm Labs' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Medipharm Labs' stock. These opinions can provide insight into Medipharm Labs' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Medipharm Stock
Medipharm Labs financial ratios help investors to determine whether Medipharm Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medipharm with respect to the benefits of owning Medipharm Labs security.